对耐药中腺信号通路的临床遗传分析
Vikas Dhiman1,2,3, Kalpita Karan4, Parthasarathy Satischandra2
1Department of Clinical Neurosciences, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Annals of Indian Academy of Neurology
|February 14, 2025
概括
这项研究研究了 hippocampal sclerosis 耐药性的腺途径,发现了大脑和血液中的特定基因表达变化. 这些发现表明的潜在生物标志物和新的治疗标.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 与海马硬化 (HS) 相关的耐药性 (DRE) 仍然是一个重大的临床挑战.
- 氨酸途径在DRE-HS中的作用尚不清楚.
- 这项研究旨在阐明enosine通路在DRE-HS.中的参与.
研究的目的:
- 分析DRE-HS患者海马体组织和外周血液中腺素通路中的基因表达.
- 确定基因表达和DRE-HS.的临床/遗传特征之间的潜在相关性.
- 探索对DRE-HS的外周血液生物标志物的实用性.
主要方法:
- 使用定量聚合酶连锁反应 (qPCR) 和免疫组织化学.
- 分析了10个腺通路相关基因的表达水平在手术切除的海马体和尸检获得的控制海马体中.
- 基因表达也评估了患者和健康对照者的外周血液.
主要成果:
- 在DRE-HS患者的海马体中观察到C-JUN,NT5E,C-FOS,ADARB1和ADORA1的显著上调.
- 相反,C-JUN,NT5E,C-FOS和ADORA1在周围血液中被降低了.
- 临床遗传分析揭示了特定基因表达 (例如,ADARB1,C-JUN,MAPK1) 与神经元分散和损失等病理特征以及发作发作的年龄之间的相关性.
结论:
- 在大脑和外围血液中表现出类似表达模式的基因有可能成为DRE-HS的生物标志物.
- 鉴定到的临床遗传相关性表明了开发DRE-HS.新型治疗策略的途径.
- 需要进一步的研究来将这些发现转化为临床应用.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
310
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
310
Arteries of the Lower Limbs
177
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
Antiepileptic Drugs: Glutamate Antagonists
271
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
271
Desensitization and Tachyphylaxis
1.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.5K
Drugs Affecting Neurotransmitter Release or Uptake
926
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
926


